Ascelia Pharma received the official minutes from its 9 September Type A meeting with the FDA and disclosed the outcome on Sunday 11 October, followed by an investor call on Monday morning.

The headline is that the FDA maintains its position that additional clinical evidence is required before Orviglance can be approved in the US, but no longer presents a new clinical study with new patients as the only way to generate it. The agency indicated that the required evidence could potentially come from a new evaluation of the existing SPARKLE image database using a different primary endpoint than the one originally applied. Management stated on the call that the minutes described this as a viable path forward,

What was clarified

First, the product quality section of the CRL now has an agreed resolution path. The issues concern drug product specifications and analytical methods rather than the manufacturing process itself, alignment was reached on the proposed strategy, and implementation has started. Management acknowledges work remains, but this removes the CMC component as a standalone obstacle.

Second, the FDA explicitly acknowledged the unmet medical need, the absence of major safety concerns, and Orviglance’s technical performance as a T1 enhancing contrast agent.

Third, and most materially, the regulatory conversation moved off the CRL’s original recommendation of a new adequate and well controlled study with new patients.

What remains open

The endpoint itself is undefined. Management said the exact type remains to be evaluated, that advisors and external specialists are being brought in, and that there are a few ideas on the table of which one or two are believed feasible. No endpoint has been proposed to the FDA, and no reading will begin before the agency has agreed to the selected endpoint.

The more substantive open question is whether an endpoint can be found that both satisfies the FDA and can be covered by the material already in hand. A different endpoint brings a different success definition applied to a fixed dataset, so the images need to carry not only the right sequences but sufficient events and sufficient statistical power under a definition they were never designed around.

Management’s framing on the call was that the value lies in extracting the information in the images in a way sufficiently different from the original read.

The process route is a Type C meeting. That sequence matters for timing: identify the endpoint, prepare the package, hold the Type C meeting, obtain alignment, then conduct the read, then resubmit.

Management didn’t give any timeline at the call, but said it would work as quickly as possible, and indicated an intention to have clarity on the FDA discussion before the end of Q2, which coincides with the current funding horizon.

Capital and partnering

The funded horizon runs into Q2 2027. Management’s stated ambition is that current financing should be sufficient to obtain clarity from the FDA, meaning the Type C outcome, not to complete the image read or a resubmission.

On partnering, management says interest from potential partners has not changed since the CRL, but that the shape of a deal has.

A transaction is now likely to include development activities rather than commercialisation alone, which shifts both the counterparty profile and the economics. It should however also be noted that an asset that has been through a full FDA review, including inspections completed without critical findings, carries less residual risk for a partner on several parameters than an unreviewed asset.

But it is still an open question whether a partner engages now or waits for the considerably greater clarity that an FDA sign-off on the chosen endpoint brings.

Management elevates Europe to a key priority

Europe is now an explicit priority alongside the US endpoint work and partnering, and management argues it would be value destruction not to pursue approval there if the existing package supports it.

No timeline has been given and no filing has been made. It is also worth being clear that the company has never quantified Europe on its own. The only disclosed frame is the USD 800m annual global addressable market with roughly half of that in the US, leaving Europe as an unlabelled share of the remainder alongside Japan and Rest of World.

The eligible population is not the constraint. Severe renal impairment in liver cancer patients is a prevalence question, and the European patient base is broadly comparable in relative terms. Price is the constraint. Management’s only stated pricing anchor is a US benchmark window of USD 3,000 to 4,500 per dose, derived from innovative PET diagnostics, and it has said explicitly that the deepest commercial work was done on the US because that is where the data is. European diagnostic pricing works differently. Contrast agents are typically funded within hospital budgets or procedure tariffs rather than reimbursed as a separate specialty product, purchasing is frequently tendered, and reference pricing across member states caps what any single market can carry. A realised European net price materially below the US level is the reasonable working assumption, and that compresses the value of a comparable procedure volume accordingly.

The practical read is that Europe is a real but structurally smaller value pool that does not substitute for the US. What makes it the right priority now is cost rather than size: testing whether the existing data and application can carry an approval in Europe is inexpensive relative to designing and running a new US image read, and it can proceed in parallel.

For the partnering process it cuts both ways. A package with a credible European route is easier to sell than one with no near-term approval anywhere.

What to watch from here

The next genuine step up in clarity comes when the endpoint is named. Management said identifying it should not take too long, and that the company will update as it builds confidence in a candidate. An announcement that a specific endpoint has been selected, together with a Type C meeting request, would be the first hard evidence that the alternative route is executable rather than theoretical, and it would let us narrow the front end of the timeline in the model.

The Type C outcome is the larger catalyst. FDA agreement on an endpoint would convert the current optionality into a defined path, at which point the remaining variables become cost, duration and funding rather than feasibility. That is also the point at which a probability of success above the markets current implied level becomes defensible. A Type C meeting that does not produce alignment would push the case back toward the scenarios where a new trial is the only route, and would reopen the question of what the company does within the one year response window that follows the CRL.

On Europe, the first disclosed contact with regulators is worth watching, and specifically whether the feedback suggests the existing data and application could support a filing. Any indication on the likely European filing route and timing would let us put a value on a region that currently sits in the model as an unquantified option.

For capital and partnering, the Q3 report on 5 November is the next scheduled update and should give an updated cash position against the stated Q2 2027 horizon. The signpost to watch after that is whether funding arrives before or after the Type C outcome, and in what form. A partnership announced before FDA alignment would be the strongest read, since it would mean a counterparty has underwritten the endpoint work on its own diligence.

Read the full release here: https://www.inderes.dk/releases/ascelia-pharma-provides-orviglancer-update-following-fda-type-a-meeting

Replay of the investor update: https://events.inderes.com/ascelia-pharma/2026-investor-update

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. Michael Friis, 12/10-2026, 13:02